安斯泰来制药ADR GAAP每股收益为162.22日元，收入为2139.2亿日元

2026-04-28 02:37

More on Astellas Pharma ADR

Astellas Pharma Inc. 2026 Q4 - Results - Earnings Call Presentation
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow
Quant snapshot: AXT, Chevron lead top-rated names as CBIZ, Grid Dynamics lag
Pfizer, Astellas win FDA priority review for Padcev in bladder cancer with Merck’s Keytruda